RxDoctor Payments Data

Jonathan Burress, DO

Cardiovascular Disease · Bristol, TNNPI 1760415582

Payments from drug & device makers

$43,222in general payments, 2019–2025

Across 573 payments — averaging $75.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$34K
  • Abbott$3K
  • Novartis$2K
  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$818
  • Amgen$342
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$33,62078%
  • Travel & lodging$2020%
  • Food & beverage$9,40022%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,222 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$114,016
Medicare patients
1,329
Services billed
2,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban504$399,384
EntrestoSacubitril/Valsartan158$118,322
XareltoRivaroxaban149$94,643
BrilintaTicagrelor51$35,334
NexlizetBempedoic Acid/Ezetimibe48$27,073
Repatha SureclickEvolocumab22$18,501
JardianceEmpagliflozin16$14,332
Ranolazine ErRanolazine97$9,228
NexletolBempedoic Acid19$8,702
Diltiazem 24hr Er (Cd)Diltiazem Hcl126$2,416
Rosuvastatin Calcium199$2,112
Atorvastatin Calcium210$1,817
Metoprolol Tartrate309$1,608
Isosorbide Mononitrate ErIsosorbide Mononitrate163$1,428
Metoprolol Succinate131$1,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$399,384504 claims
NovartisEntresto$2,064$118,322158 claims
Johnson & JohnsonXarelto$197$94,643149 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$34,178$35,77567 claims
AstraZenecaBrilinta$246$35,33451 claims
Boehringer IngelheimJardiance$213$14,33216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →